☆ 4.3 Letter

Successful management of anti-MDA5-positive rapidly progressive interstitial lung disease-A case series

INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2023)

Forced vital capacity predicts the survival of interstitial lung disease in anti-MDA5 positive dermatomyositis: a multi-centre cohort study

Wanlong Wu et al.

Summary: This study aimed to establish and validate a clinical prediction model for 6-month all-cause mortality in Chinese patients with anti-MDA5 positive DM-ILD. The results showed that a categorical predictor based on forced vital capacity (FVC)% was identified and validated as an independent prognostic factor, which could effectively distinguish the risk stages in patients and facilitate risk stratification in clinical practice.

RHEUMATOLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

GAP Score and CA-153 Associated with One-Year Mortality in Anti-MDA-5 Antibody-Positive Patients: A Real-World Experience

Chih-Wei Tseng et al.

Summary: This study identified factors associated with 1-year mortality in patients positive for anti-MDA-5 antibody, including GAP scores, CA-153 levels, pulmonary function test results, and other clinical parameters. Prompt diagnosis and effective management are crucial for the survival of these patients.

JOURNAL OF CLINICAL MEDICINE (2021)

添加到收藏夹

Article Respiratory System

2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease

Yasuhiro Kondoh et al.

Summary: The prognosis of patients with connective tissue disease (CTD) has improved, but interstitial lung disease (ILD) associated with CTD remains a refractory condition and a leading cause of mortality. The guide focusing on CTD-ILD, published through collaboration between Japanese Respiratory Society and Japan College of Rheumatology, aims to help standardize medical care for CTD-ILD and promote future research by addressing unresolved issues.

RESPIRATORY INVESTIGATION (2021)

添加到收藏夹

Article Medicine, General & Internal

Combination Therapy with Rituximab, Tofacitinib and Pirfenidone in a Patient with Rapid Progressive Interstitial Lung Disease (RP-ILD) Due to MDA5 Antibody-Associated Dermatomyositis: A Case Report

Tsai-Hung Yen et al.

Summary: Anti-MDA5-associated dermatomyositis with RP-ILD is a severe condition with poor prognosis. The case report describes successful treatment with a combination of rituximab, tofacitinib, and pirfenidone leading to significant and sustainable improvement in symptoms.

MEDICINA-LITHUANIA (2021)

添加到收藏夹

Letter Medicine, General & Internal

Tofacitinib in Amyopathic Dermatomyositis-Associated Interstitial Lung Disease

Zhiwei Chen et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Rheumatology

Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis

Kazuhiro Kurasawa et al.

RHEUMATOLOGY (2018)

添加到收藏夹

Successful management of anti-MDA5-positive rapidly progressive interstitial lung disease-A case series

相关参考文献

Forced vital capacity predicts the survival of interstitial lung disease in anti-MDA5 positive dermatomyositis: a multi-centre cohort study

GAP Score and CA-153 Associated with One-Year Mortality in Anti-MDA-5 Antibody-Positive Patients: A Real-World Experience

2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease

Combination Therapy with Rituximab, Tofacitinib and Pirfenidone in a Patient with Rapid Progressive Interstitial Lung Disease (RP-ILD) Due to MDA5 Antibody-Associated Dermatomyositis: A Case Report

Tofacitinib in Amyopathic Dermatomyositis-Associated Interstitial Lung Disease

Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis

导出引文

分享论文